康柏西普与雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的疗效及安全性分析

目的 比较康柏西普与雷珠单抗治疗视网膜中央静脉阻塞（central retinal vein occlusion，CRVO）继发黄斑水肿的效果和安全性。方法 将陕西省杨凌示范区医院自2015年6月-2017年1月纳入的CRVO继发黄斑水肿患者102例作为研究对象，随机分为两组，即使用康柏西普治疗的A组50例（50眼），使用雷珠单抗治疗的B组52例（52眼），观察治疗后1、3、6个月时患者视力恢复情况和黄斑部视网膜厚度变化情况，评价不同药物的治疗效果和安全性。结果 治疗6个月后A组患者视力提高率（52.00%）高于B组（30.77%），差异具有统计学意义（P<0.05）；两组患者的黄斑部视网膜厚度的改善A组优于B组，且各个复诊时间点比较，差异均具有统计学意义（P<0.05）。两组不良反应发生率分别为8.00%和11.54%，差异无统计学意义。结论 康柏西普治疗CRVO继发黄斑水肿的临床效果优于雷珠单抗，但二者的安全性差异不显著，有待于进一步长期大样本研究证实。

Efficacy and safety of Conbercept Ophthalmic Injection and Ranibizumab Injections in the treatment of CRVO macular edema

Objective To study the therapeutic effect and safety of Conbercept Ophthalmic Injection and Ranibizumab Injections in the treatment of retinal central venous obstruction (CRVO) macular edema.Methods 102 patients with CRVO macular edema admitted in our hospital from January 2014 to January 2017 were divided into two groups according to the order of admission. In group A, 50 patients (50 eyes) were treated with Conbercept Ophthalmic Injection. In group B, 52 patients (52 eyes) were treated with Ranibizumab Injections. After treatment, the changes of visual acuity and macular fovea were observed at 1 month, 3 months and 6 months after treatment. The therapeutic effect and safety of different drugs.Results The improvement rate of visual acuity was 52.00% in group A after 6 months of treatment, which was significantly higher than that in group B (30.77%). The difference was statistically significant (P< 0.05). After treatment, the retinal thickness improvement in the macular region of A group was better than that in the B group, and the differences were statistically significant (P< 0.05). The incidence of adverse reactions of the two groups were 8.00% and 11.54% respectively, the difference was not significant.Conclusion Conbercept Ophthalmic Injection and Ranibizumab Injections have good clinical effect and safety in patients with CRVO macular edema, the difference is not significant, and the clinical observation is needed to further expand the number of samples and the drug cycle.